UA42695C2 - Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука - Google Patents

Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука

Info

Publication number
UA42695C2
UA42695C2 UA94129260A UA94129260A UA42695C2 UA 42695 C2 UA42695 C2 UA 42695C2 UA 94129260 A UA94129260 A UA 94129260A UA 94129260 A UA94129260 A UA 94129260A UA 42695 C2 UA42695 C2 UA 42695C2
Authority
UA
Ukraine
Prior art keywords
remainder
anthracycline
nhd
mol
leu
Prior art date
Application number
UA94129260A
Other languages
English (en)
Russian (ru)
Inventor
Франческо АНГЕЛУЧЧІ
Франческо АНГЕЛУЧЧИ
Марія ГРАНДІ
Мария Гранди
Антоніно СЮАРАТО
Антонино СЮАРАТО
Original Assignee
Фармація Енд Апджон С.П.А.
Фармация Энд Апджон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармація Енд Апджон С.П.А., Фармация Энд Апджон С.П.А. filed Critical Фармація Енд Апджон С.П.А.
Publication of UA42695C2 publication Critical patent/UA42695C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Даний винахід належить до розчинних синтетичних полімер-зв’язаних антрациклінів, їх отримання та до фармацевтичних композицій, що їх містять. Фармацевтична композиція, що має протипухлинну активність, містить як активний компонент полімер-зв’язаний антрациклін, що являє собою співполімер, що складається з трьох ланок, які відповідають формулам (1), (2), (3) у яких R1 – С1-С6-гидроксиалкіл, Y - залишок пептиду -Phe-Leu-Gly-, NHD - залишок антрациклінаміноглікозиду H2ND, Z - гідроксигрупа або залишок загальної формули –NHR1, х, у, z - молярні частини відповідно ланок (1), (2), (3) у загальному співполімері, та х - від 70 до 98 мол.%, у - від 1 до 29 мол.%, z - від 1 до 29 мол.%, чи похідне антрацикліну загальної формули HY-NHD, де Y представляє залишок пептиду -Phe-Leu-Gly-, NHD представляє залишок антрациклінаміноглікозиду H2ND, у ефективній кількості.
UA94129260A 1993-05-11 1994-04-08 Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука UA42695C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939309663A GB9309663D0 (en) 1993-05-11 1993-05-11 Biologically active compounds
PCT/EP1994/001100 WO1994026311A1 (en) 1993-05-11 1994-04-08 Anthracycline conjugates, their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
UA42695C2 true UA42695C2 (uk) 2001-11-15

Family

ID=10735264

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94129260A UA42695C2 (uk) 1993-05-11 1994-04-08 Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука

Country Status (25)

Country Link
US (1) US5571785A (uk)
EP (1) EP0649312B1 (uk)
JP (1) JPH08502519A (uk)
KR (1) KR100330635B1 (uk)
CN (1) CN1098106C (uk)
AT (1) ATE203414T1 (uk)
AU (1) AU671741B2 (uk)
CA (1) CA2136438C (uk)
DE (1) DE69427799T2 (uk)
DK (1) DK0649312T3 (uk)
ES (1) ES2161764T3 (uk)
FI (1) FI112602B (uk)
GB (1) GB9309663D0 (uk)
GR (1) GR3036978T3 (uk)
HU (2) HUT70509A (uk)
IL (1) IL109528A (uk)
MY (1) MY110974A (uk)
NZ (1) NZ265266A (uk)
PL (1) PL175325B1 (uk)
PT (1) PT649312E (uk)
RU (1) RU2145965C1 (uk)
TW (1) TW268015B (uk)
UA (1) UA42695C2 (uk)
WO (1) WO1994026311A1 (uk)
ZA (1) ZA943212B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CA2445985A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
US7049285B2 (en) * 2001-10-31 2006-05-23 Myung-Ok Park Biocompatible polymers including peptide spacer
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
JP6744826B2 (ja) 2014-06-13 2020-08-19 バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC Ｆａｐ活性化治療剤及びそれに関連する使用
US9737556B2 (en) * 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
JPS60246400A (ja) * 1984-05-22 1985-12-06 Ajinomoto Co Inc アントラサイクリン系化合物及び制ガン剤
US5169937A (en) * 1986-11-18 1992-12-08 The Scripps Research Institute Method for producing stable glycosylated hemoglobin
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents

Also Published As

Publication number Publication date
EP0649312A1 (en) 1995-04-26
DE69427799T2 (de) 2002-05-02
IL109528A (en) 1998-08-16
ZA943212B (en) 1995-01-18
RU2145965C1 (ru) 2000-02-27
KR950702201A (ko) 1995-06-19
US5571785A (en) 1996-11-05
CN1098106C (zh) 2003-01-08
ES2161764T3 (es) 2001-12-16
AU6566694A (en) 1994-12-12
FI946128A0 (fi) 1994-12-28
CN1108454A (zh) 1995-09-13
PL306861A1 (en) 1995-04-18
GB9309663D0 (en) 1993-06-23
KR100330635B1 (ko) 2002-09-17
FI946128A (fi) 1994-12-28
AU671741B2 (en) 1996-09-05
FI112602B (fi) 2003-12-31
HU211538A9 (en) 1995-12-28
WO1994026311A1 (en) 1994-11-24
RU94046336A (ru) 1996-10-27
DK0649312T3 (da) 2001-11-12
DE69427799D1 (de) 2001-08-30
CA2136438A1 (en) 1994-11-24
NZ265266A (en) 1996-06-25
IL109528A0 (en) 1994-08-26
ATE203414T1 (de) 2001-08-15
PL175325B1 (pl) 1998-12-31
MY110974A (en) 1999-07-31
GR3036978T3 (en) 2002-01-31
HUT70509A (en) 1995-10-30
PT649312E (pt) 2002-01-30
EP0649312B1 (en) 2001-07-25
TW268015B (uk) 1996-01-11
HU9403811D0 (en) 1995-03-28
JPH08502519A (ja) 1996-03-19
CA2136438C (en) 2004-09-14

Similar Documents

Publication Publication Date Title
IL118047A (en) Sulfated oligosaccharides pharmaceutical compositions containing them and preparation of sulfated hexopyranose homooligosaccharides
BG105851A (en) Gcsf conugates
AR008378A1 (es) Conjudados de interferon
GB0124967D0 (en) Cosmetic and personal care compositions
TW266201B (uk)
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
HUP9601564A2 (hu) Irbesartant tartalmazó gyógyszerkészítmények
EP0966456A4 (en) THE ACTIVE SUBSTANCE RESISTANCE IN CANCER CHEMOTHERAPY REVERSING TAXOIDS AND PHARMACEUTICAL PREPARATIONS THEREOF
IL123293A (en) Piperidine derivatives, their preparation and pharmaceutical compositions containing them
DE60204820D1 (de) Antistatische Polymerzusammensetzungen
ES2175748T3 (es) Monomeros y copolimeros vinilicos basados en azucares utiles en adhesivos reducibles a pasta y otras aplicaciones.
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
BR9808928A (pt) Complexo molecular e liberação controlada dealfa hidroxiácidos
UA42695C2 (uk) Полімерзв'язаний антрациклін, фармацевтична композиція та проміжна сполука
ES2133380T3 (es) Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion.
BR0007275A (pt) Naftopiranos e fenantropiranos anelados em c5-c6com um grupo bicìclico e composições e matrizes
BR1100143A (pt) Composto, e, composição farmacêutica.
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
BR9408130A (pt) Composições de copolímeros aleatórios
MY102186A (en) Antitumor anthracycline glycosides, their preparation intermediate thereof, and compositions and use thereof
EP0305972A3 (en) 3'- demethoxyepipodophyllotoxin glucoside derivatives
IL93258A0 (en) Anthracycline glycoside derivatives,their preparation and pharmaceutical compositions containing them
ES8703872A1 (es) Procedimiento para preparar derivados de isoquinolina.